



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)

Fax : 0091-11-26498341,26494708, Phone: 0091-11-26494519-24

E-mail: admin@jagsonpal.com

CIN: LT499DL1978PLC009181

JPL/SEC/LODR-Comp/reS-Not1

Date : August 14th, 2017

The National Stock Exchange of India
Ltd.
Exchange Plaza,
Bandara-Kurla Complex
Bandra (E), Mumbai - 400 051.
Ph. 022-26598452

The Bombay Stock Exchange Limited
Pnerozephoy Jeejeebhoy Tower
Dalal Street,
Mumbai - 400 001
Ph. 022-22721234

**SUB: UN-AUDITED STANDALONE FINANCIAL RESULTS FOR QUARTER ENDED
30.06.2017 & LIMITED REVIEW.**

Dear Sir,

Please find enclosed herewith un-audited financial results for the quarter ended 30th June, 2017.

Thanking you.

Yours faithfully,
for JAGSONPAL PHARMACEUTICALS LIMITED

R K KAPOOR
COMPLIANCE OFFICER CUM COMPANY SECRETARY





JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DLI978PLC009181

PART-I Particulars	Rs. in lacs			
	3 months ended 30.06.2017 Unaudited	3 months ended 31.03.2017 Audited	3 months ended 30.06.2016 Unaudited	12 Months ended 31.03.2017 Audited
	1 Income from operations			
a Net sales/Income from Operations (Net of excise duty)	2689.65	2935.89	4011.02	14387.05
b Other Operating Income	0	11.87	13.15	39.04
Total Income from operations (net)	2689.65	2947.76	4024.17	14426.09
2 Expenses				
a Cost of materials consumed	1803.09	1031.85	1673.90	5387.47
b Purchases of stock-in-trade	425.42	527.31	374.99	1346.42
c. Changes in inventories of finished goods, work in	-826.45	-690.23	-422.43	-838.92
d. Employee benefits expenses	958.66	999.78	1116.11	4095.20
e. Depreciation and amortisation expense	26.47	22.88	70.43	199.40
f. Other expenses	718.05	1030.73	1036.16	3820.02
Total expenses	3105.24	2922.32	3849.16	14009.59
3 Profit from Operations before Other Income, Finance Cost and Exceptional items (1-2)	-415.59	25.44	175.01	416.50
4 Other Income	12.15	7.72	0.03	7.84
5 Profit from ordinary activities before finance cost and Exceptional items (3+4)	-403.44	33.16	175.04	424.34
6 Finance Cost	18.63	23.42	94.87	264.48
7 Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	-422.07	9.74	80.17	159.86
8 Exceptional Items				1279.81
9 Profit/(+)/Loss(-) from Ordinary Activities before tax (7+8)	-422.07	9.74	80.17	1439.67
10 Tax expense		-71.84	16.03	253.20
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	-422.07	81.58	64.14	1186.47
12 Extraordinary Items (net of tax expense Rs. lacs)	-422.07	81.58	64.14	1186.47
13 Net Profit/(+)/Loss(-) for the period(11-12)	1309.90	1309.90	1309.90	1309.90
14 Paid up Eq. Sh. Cap.(Face value Rs. 5)				
15 Reserves excluding Revaluation reserves as per Balance sheet of pr. Accounting yr				9681.49
16 Earnings Per Share (before extraordinary items)				
a. Basic (Rs.)	-1.61	0.31	0.24	4.53
b. Diluted (Rs.)	-1.61	0.31	0.24	4.53

Notes

- 1) The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 14, 2017.
- 2) The Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- 3) Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.
- 4) The above results are available on website of the company www.jagsonpal.com.
- 5) These unaudited financial results have been subjected to limited review by the Statutory Auditors of the Company who have expressed an unqualified / unmodified conclusion on these results.
- 6) The Company has adopted Indian Accounting Standards (referred to as 'Ind AS') with effect from 1st April 17 and accordingly these financial results alongwith the comparatives have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 on 'Interim Financial Reporting' as prescribed under section 133 of the Companies ACT, 2013 and read with relevant rules issued thereunder and other accounting standards generally accepted in India.
- 7) Reconciliation between results previously reported under erstwhile Indian GAAP and as presented now under Ind AS are given below:-

Particulars	Quarter ended 30.06.2016	Year to date ended 30.06.2016
Net Profit for the period as per Indian GAAP	64.14	64.14
Adjustments :		
Net Profit for the period as per Ind AS	64.14	64.14
Total Comprehensive Income as per Ind AS	64.14	64.14

- 8) The Ind AS compliant comparative figures for the quarter ended June 30, 2016 and Year to date June 30, 2016 have not been subjected to review or audit. However, the company's management has exercised necessary due diligence to ensure that such financial results provide true and fair view of its affairs.



Place : New Delhi
Date : 14.08.2017

**For P.P. Thukral & Co.,
Chartered Accountants**

(SURESH SETHI)
(Partner)
M.No.-089316
F.R. No.-000632N

By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director
DIN No 00059492

Review Report to Members of Jagsonpal Pharmaceuticals Limited, New Delhi.

We have reviewed the accompanying statement of unaudited financial results of Jagospal Pharmaceuticals Limited for the period ended 30.06.2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquires of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.P. Thukral & Co.
Chartered Accountants



Place : New Delhi
Date: 14.08.2017


SURESH SETHI
Partner

Firm's Registration Number: 000632N
Membership No. : 089318



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24
CIN No. L74899DLI978PLC009181

JPL/Stock-Corr-2013	August 14th, 2017
The Manager - Listing The National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051	The Manager - Listing The Bombay Stock Exchange Ltd. Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001.
CM Quote : JAGSNPHARM	Scrip Code : 507789
OUT-COME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON 14.08.2017	


Sir,

- Performance of the 1st Quarter and three months ended 30.06.2017 (Un-audited) was placed before the Board having reviewed by the Audit Committee. The issue was discussed.
- Approval of Quarterly performance and three months ended 30.06.2017 as approved by the Board of Directors and resolution in this regard was passed with an authority to Managing Director to publish in newspapers and send same to National Stock Exchange of India Limited (NSE) & Bombay Stock Exchange Limited (BSE).
- Auditors Limited Review statement is enclosed.
- Cost Audit Report was also approved and taken on record by the Board.
- Other routine matters were discussed by Board and taken care.
- Any another matter with the permission. Meeting concluded with vote of thanks,
- The meetings commence at 11.00 a. m. and concluded at 1.45 p.m.
- Audit Committee Chairman has been replaced by Mr. Bharat Sinh.

Thanking you,

Yours faithfully,
For JAGSONPAL PHARMACEUTICALS LIMITED


R K KAPOOR
COMPLIANCE OFFICER & COMPANY





JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DLI978PLC009181

JPL/SEC/STOCK-CORR-2013	Date : August 14th, 2017
The National Stock Exchange of India Ltd. Exchange Plaza, Kamala Mills Compound Bandra-Kurla Complex Bandra (E), Mumbai - 400 051.	The Manager - Listing The Bombay Stock Exchange Ltd. Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001.
CM Quote : JAGSNPHARM	
<i>Subject : Declaration Under Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</i>	

Sir,

Pursuant to **regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**. We declare that the Auditors Limited Review for quarter ended 30.06.2017 given by Statutory Auditors is clean and does not have any qualification or reservation and no figure have been modified / adjusted.

Please take on records.

Thanking you,

Yours faithfully,

For **JAGSONPAL PHARMACEUTICALS LTD.**

(R. K. KAPOOR)
COMPANY SECRETARY.

